[Risk factors for hematologic toxicity and multifaceted analysis of blood in Hodgkin's disease: a model for hematologic toxicity].
Basic hematological features of CEA/ABVD medication for Hodgkin's disease were studied. An effective model was worked out on the principle of data discrimination for predicting different leukocytic toxicities induced by cytostatics-1 administration, once in two weeks. It might predict individual limits (dosage and intervals) of a chemotherapy course unless a colony-stimulation technique is used.
P V
PV
Datsenko
P N
PN
Podol'skiĭ
G A
GA
Pan'shin
V M
VM
Sotnikov
V K
VK
Bozhenko
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D016190:Carboplatin / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D016002:Discriminant Analysis; D004317:Doxorubicin / Q000009:adverse effects; D004334:Drug Administration Schedule; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced*; D006689:Hodgkin Disease / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D011379:Prognosis; D012307:Risk Factors; D014747:Vinblastine / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D016190:Carboplatin